The Argus II retinal chip will be launched in the next few months, after receiving FDA approval earlier this year. Medical centres in 12 major US markets have been selected as implanting centres and will soon begin accepting patients.
Argus II, developed by Second Sight Medical Products, converts video images captured by a miniature camera, housed in the patient’s glasses, into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes on the surface of the retina.
These pulses are intended to stimulate the retina’s remaining cells resulting in the corresponding perception of patterns of light in the brain. Patients then learn to interpret these visual patterns thereby regaining some visual function.
Argus II, developed by Second Sight Medical Products, converts video images captured by a miniature camera…
RP is a rare inherited, degenerative eye disease that often results in profound vision loss. There is no cure.
Second Sight’s Brian Mech said the implant centres were chosen “for their cutting-edge approach to medicine and unparalleled commitment to patient care” after an intensive selection process.
Argus II is the result of more than 20 years of work in the field, three clinical trials, more than USD$100 million in public investment and an additional US$100 million in private investment.